Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLC
Status:
RECRUITING
Trial end date:
2025-09-04
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to investigate the efficacy, safety and tolerability of PD-1/CTLA-4 inhibitor (Cadonilimab) combination with chemotherapy as first-line treatment for PD-L1 negative advanced non small cell lung cancer patients. And also explore the potential biomarkers for predicting the efficacy of PD-1/CTLA-4 inhibitor for advanced non small cell lung cancer.